Call to arrange a consultation
+1 416 777 0888

Nathaniel Dillonsmith

Associate

Nathaniel Dillonsmith practices exclusively in the area of intellectual property law, focusing on pharmaceutical patent litigation and proceedings under the Patented Medicines (Notice of Compliance) Regulations. Nathaniel completed his J.D. and Bachelor of Engineering Science in Integrated Engineering at the University of Western Ontario. Nathaniel was called to the Ontario Bar in 2014 and practiced at a prominent litigation boutique in downtown Toronto for several years before joining Sprigings Intellectual Property Law in March of 2018.

Education

  • B.SC.E., University of Western Ontario
  • J.D., University of Western Ontario

Bar Admission

  • Ontario, 2014

Nathaniel Dillonsmith

Recent Cases

Application for leave to appeal to the Supreme Court of Canada in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,791,171 (apixaban)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,461,202 (apixaban)

Interlocutory appeal in a patent impeachment action relating to Patent No. 2,261,630 (infliximab)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,540,547, 2,596,133, 2,376,596 and 2,407,556 (trastuzumab)

Interlocutory appeal in a patent impeachment action regarding Patent No. 2,261,630 (infliximab)

Patent infringement case regarding Patent No. 2,407,556 (trastuzumab)

Patent impeachment case regarding Patent No. 2,540,547 (trastuzumab)

Patent impeachment case regarding Patent No. 2,329,829 (trastuzumab)

Patent impeachment case regarding Patent No. 2,376,596 (trastuzumab)

Patent impeachement and patent infringement case regarding Patent No. 2,261,630 (infliximab).

Patent infringement case regarding Patent No. 1,336,777 (clopidogrel).

Patent infringement case regarding Patent No. 1,336,777 (clopidogrel).

More people

Interested in joining the team?

We are always on the lookout for talented individuals.

View Careers